Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05048797 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
A Phase 3 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 454
- Enrollment target
- 20
- Study locations
NCT05048797 is a Phase 3 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 454 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT05048797, a Phase 3 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 454 participants
- Enrollment target
- 20
- Study locations
Study Summary
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Trastuzumab Deruxtecan
Study Locations (20)
California
- Research Site - Los Alamitos
- Research Site - Los Angeles
- Research Site - Orange
- Research Site - San Francisco
- Research Site - Santa Monica
New Jersey
- Research Site - Basking Ridge
- Research Site - Middletown
- Research Site - Montvale
- Research Site - New Brunswick
New York
- Research Site - Commack
- Research Site - Harrison
- Research Site - New York
- Research Site - Uniondale
Alaska
- Research Site - Anchorage
Maryland
- Research Site - Silver Spring
Massachusetts
- Research Site - Boston
Michigan
- Research Site - Ann Arbor
Pennsylvania
- Research Site - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 454 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05048797
The ClinicalTrials.gov registry entry for NCT05048797 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 454 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced or Metastatic Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05048797 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT05048797 about?
NCT05048797 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations". DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
What is the current status of trial NCT05048797?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 454 participants. The study started on 2021-10-28. Estimated completion is 2027-07-30.
What conditions does trial NCT05048797 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05048797?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT05048797?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05048797 being conducted?
This trial has 20 study locations across Alaska, California, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.